Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 4/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22295667 | 0.94 | MEN1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL6373762 | 0.94 | MEN1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL30729296 | 0.94 | MEN1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL29876413 | 0.94 | MEN1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL3041931 | 0.94 | MEN1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL29578356 | 0.94 | MEN1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| Acetic Acid SCHEMBL30771284 | 0.92 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL29762027 | 0.89 | MEN1 (0.45) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL30423293 | 0.86 | MEN1 (0.43) | ALDH1A1MEN1KMT2ALMNACTSC | |
| SCHEMBL31721020 | 0.86 | MEN1 (0.43) | ALDH1A1MEN1KMT2ALMNACTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-0885215-B1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1609790-A2 | Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | Abbott Laboratories (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2002017912-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1003740-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGOISTS | Abbott Laboratories (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | ALDH1A1 1420/4885MEN1 517/4885KMT2A 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.